Literature DB >> 17669510

Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia.

Ying-Jay Liou1, Ying-Chieh Wang, Jen-Yeu Chen, Ya-Mei Bai, Chao-Cheng Lin, Ding-Lieh Liao, Tzu-Ting Chen, Mao-Liang Chen, Geng-Han Mo, I-Ching Lai.   

Abstract

Tardive dyskinesia (TD) is a neurological disorder characterized by irregular, non-rhythmic, choreoathetotic and involuntary movements in single or multiple body regions. Chronic administration of typical antipsychotic agents, which predominantly act on dopamine receptors, implicates the dopamine system in susceptibility to TD. An alternative to this dopaminergic supersensivity hypothesis in understanding the pathogenesis of TD is the glutamatergic neurotoxicity hypothesis, which implicates the N-methyl-D-aspartate (NMDA) receptor in TD pathogenesis. In the present study, the association between three polymorphisms (T-200G, C366G and C2664T) of the GRIN2B gene, which encodes the 2B subunit of the NMDA receptor, and the occurrence and severity of TD were investigated in 273 Chinese schizophrenic patients receiving long-term antipsychotic treatment (TD: 142, non-TD: 133). There was no significant association between patients' genotype and allele frequencies and TD occurrence. Among the TD patients, the differences in the total scores on the Abnormal Involuntary Movement Scale (AIMS) among the three genotypes of each polymorphism were not significant. Because the three studied markers are in weak linkage disequilibrium with each other, haplotype-based association was not carried out. We conclude that genetic variations in the human GRIN2B gene probably do not play a major role in susceptibility to, or severity of TD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17669510     DOI: 10.1016/j.psychres.2006.08.007

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  8 in total

Review 1.  Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.

Authors:  Vladimir Lerner; Chanoch Miodownik
Journal:  Curr Psychiatry Rep       Date:  2011-08       Impact factor: 5.285

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans.

Authors:  Ke Xu; Robert H Lipsky
Journal:  Exp Biol Med (Maywood)       Date:  2014-09-21

4.  Drug-induced parkinsonism.

Authors:  Hae-Won Shin; Sun Ju Chung
Journal:  J Clin Neurol       Date:  2012-03-31       Impact factor: 3.077

5.  DRD and GRIN2B polymorphisms and their association with the development of impulse control behaviour among Malaysian Parkinson's disease patients.

Authors:  Shahidee Zainal Abidin; Eng Liang Tan; Soon-Choy Chan; Ameerah Jaafar; Alex Xuen Lee; Mohd Hamdi Noor Abd Hamid; Nor Azian Abdul Murad; Nur Fadlina Pakarul Razy; Shahrul Azmin; Azlina Ahmad Annuar; Shen Yang Lim; Pike-See Cheah; King-Hwa Ling; Norlinah Mohamed Ibrahim
Journal:  BMC Neurol       Date:  2015-04-22       Impact factor: 2.474

Review 6.  Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders.

Authors:  Florence Cf Chang; Victor Sc Fung
Journal:  Pharmgenomics Pers Med       Date:  2014-10-13

7.  NMDA receptor genotypes associated with the vulnerability to develop dyskinesia.

Authors:  S A Ivanova; A J M Loonen; P Pechlivanoglou; M B Freidin; A F Y Al Hadithy; E V Rudikov; I A Zhukova; N V Govorin; V A Sorokina; O Y Fedorenko; V M Alifirova; A V Semke; J R B J Brouwers; B Wilffert
Journal:  Transl Psychiatry       Date:  2012-01-10       Impact factor: 6.222

8.  Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.

Authors:  Cheng-Ta Li; Kun-Hsien Chou; Tung-Ping Su; Chu-Chung Huang; Mu-Hong Chen; Ya-Mei Bai; Ching-Po Lin
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.